Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) is dated June 3, 2024. The report details a Securities Purchase Agreement entered into on May 31, 2024, with a select institutional accredited investor. The transaction involves a three-tranche private placement of American Depositary Shares (ADS) and pre-funded warrants to fund the advancement of the company's lead asset, BNC210, for social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD).
Key Financial Metrics
- Initial Proceeds: The first tranche closed on June 3, 2024, generating aggregate gross proceeds of $7.5 million.
- Transaction Structure: The first tranche consisted of 1,296,486 ADSs and 6,279,905 Pre-Funded Warrants sold at a combined price of $0.99 per unit.
- Warrant Terms: The first tranche includes a five-year cash purchase warrant to buy up to 12,652,572 ADSs at an exercise price of $0.99 per ADS.
- Maximum Potential Proceeds: Assuming full exercise of warrants and consummation of all tranches, total gross proceeds could reach approximately $70.0 million.
- Liquidity Outlook: Proceeds from the first tranche, combined with existing cash and marketable securities, are expected to fund operations into the third quarter of 2025.
Material Changes and Transaction Details
The filing announces a significant capital raise structured in three tranches:
- Tranche 1 (Closed): $7.5 million gross proceeds received immediately.
- Tranche 2 (Conditional): Up to an additional $25.0 million is available if regulatory milestones are met (FDA correspondence regarding BNC210 for PTSD or by December 31, 2024). This tranche becomes mandatory if the company's 10-day volume-weighted average price reaches $8.00 with at least $100 million in trading volume.
- Tranche 3 (Conditional): Up to an additional $25.0 million is available if milestones are met (interim blinded safety review of Phase-3 PTSD study or by December 31, 2025). Similar to Tranche 2, this becomes mandatory under specific stock price and volume conditions ($8.00 VWAP and $100 million volume).
Guidance, Outlook, and Risks
Use of Proceeds: Net proceeds will fund BNC210 registrational programs for SAD and PTSD, business development, working capital, and general corporate purposes. Specifically, the initial funding enables the execution of the planned Phase 3 study in SAD.
Registration Rights: The company entered into a Registration Rights Agreement requiring a registration statement to be filed within 30 days and declared effective within 60 days (or 120 days if reviewed by the SEC).
Risks and Contingencies: The majority of the potential capital ($50 million) is contingent on achieving specific regulatory milestones or stock price performance. The securities were sold under Section 4(a)(2) of the Securities Act and are not registered for public resale until the registration statement becomes effective.
Investor Verification Checklist
- Verify the company's current cash, cash equivalents, and marketable securities balance to confirm the runway into Q3 2025.
- Monitor the status of the FDA End-of-Phase 2 meeting and breakthrough designation status for BNC210 to assess the likelihood of Tranche 2 funding.
- Track the interim blinded safety review of the BNC210 Phase-3 PTSD study for Tranche 3 eligibility.
- Review the filed Registration Statement (Exhibit 99.2) to confirm the timeline for the investor's ability to resell shares.
- Assess the dilution impact of the 12.6 million accompanying warrants and potential future warrant issuances.